Copyright
©The Author(s) 2022.
World J Clin Cases. Apr 16, 2022; 10(11): 3321-3333
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3321
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3321
Figure 1 Some signals in the Wnt/β-catenin pathway by anti-signaling antibodies or intervening in their gene transcription to inhibit hepatocellular carcinoma growth.
Using anti-signaling molecule antibodies or intervening in their gene transcription to inhibit Wnt/β-catenin pathway activation could suppress proliferation of hepatocellular carcinoma (HCC) cells or HCC growth. GPC-3: Glypican-3; HCC: Hepatocellular carcinoma; sCLU: Secretory clusterin; TCF: T-cell factor; SULF2: Sulfatase 2; pGSK3β: Phosphorylated glycogen synthase kinase 3β.
- Citation: Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333
- URL: https://www.wjgnet.com/2307-8960/full/v10/i11/3321.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i11.3321